Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Clinical Trials in Israel / NCT06968312
Recruiting Not applicable

Hexadecanal as an Addon to Cognitive Processing Therapy for PTSD

NCT06968312 · tracked via the Priya Life Science Israel tracker
Sponsor
Tel Aviv University
Phase
Not applicable
Started
2025-05-05
Last updated
2025-05-16

Condition(s) studied

Post Traumatic Stress Disorder (PTSD)

Investigational drug(s) / intervention(s)

Cognitive Processing Therapy + HexadecanalHexadecanal - Molecule Distribution in the Therapy room

Cognitive Processing Therapy + Hexadecanal: Cognitive Processing Therapy is a protocolized, trauma-focused, CBT type treatment for PTSD.

Hexadecanal - Molecule Distribution in the Therapy room: Distribution of a naturally secreted molecule from body odor (Hexadecanal).

Study summary

This RCT investigates whether Cognitive Processing Therapy, a first line treatment for PTSD, can be enhanced by the use of the odor molecule Hexadecenal (HEX). HEX is secreted from body odor and has been shown to promotes psychological well-being and positive social interaction. For the active group Hex will be diffused in the treatment room during all treatment sessions. For the control group a vehicle placebo molecule will be diffused. Both therapists and patients will be blind to study condition.

Eligibility

Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: * Diagnosis of PTSD according to DSM-5 * Age 18 years and over * Eligible for CPT treatment at the National Center for Traumatic Stress and Resilience Exclusion Criteria: * Bipolar disorder, psychosis, neurological disorders * Drug Addiction * Parallel psychotherapy * Congenital or acquired anosmia.

Primary outcome measure(s)

Trial sites (1)

FacilityCityRegionStatus
Tel Aviv University Tel Aviv Israel Recruiting

More Tel Aviv University trials in Israel

Shiatsu for Chronic Non-Inflammatory Pain in Children and Adolescents Recruiting
Improving Self-regulation in Individuals With ADHD Through Adapted Karate Training Starting soon
AI-Guided Sarcopenia Risk Assessment and Detection Active, not recruiting
Exposure by Assessment: Effects of Daily AMQ-Based EMA of an Intrusive Trauma Memory in PTSD Recruiting
Emotion Regulation Selection Flexibility Training for PTSD Patients Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06968312 on ClinicalTrials.gov ↗ ← All trials in Israel